Bottom line
RAAR vs NCLO: the short answer
RAAR (Reckoner Yield Enhanced AAA CLO Reinvesting ETF) and NCLO (Nuveen AA-BBB CLO ETF) are both etfs.
But NCLO is far broader, holding 107 positions to 2 for RAAR, so beyond the top names it adds exposure RAAR doesn't have.
Updated Nov 19, 2026
RAAR vs NCLO side by side
| RAAR | NCLO | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Tortoise | Nuveen / TIAA |
| Category | Large Blend | Bank Loan / Floating Rate |
| Expense ratio | — | 0.26% |
| Annual cost per $10k | — | $26 |
| 10-yr cost on $10k (prospectus) | — | $331 |
| Max front load | None | None |
| 12b-1 fee | — | 0% |
| 1-yr return | — | — |
| 5-yr return (annualized) | — | — |
| 10-yr return (annualized) | — | — |
| Best quarter | — | — |
| Worst quarter | — | — |
| Net assets (fund) | $12.7M | $152.2M |
| Number of holdings | 2 | 107 |
| Portfolio turnover | — | 25% |
| Returns as of | — | — |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
RAAR and NCLO share none of their top holdings.
RAAR top 10
- Reckoner Yield Enhanced AAA CL — 99.09%
- U.S. Bank Money Market Deposit Account — 0.91%
NCLO top 10
- AIMCO CLO Series 2015-A — 2.64%
- OHA Credit Funding 10-R Ltd — 2.31%
- OCP CLO 2025-40 Ltd — 2.31%
- Goldentree Loan Management US Clo 17 Ltd — 2.23%
- MidOcean Credit CLO XVI — 2.14%
- Neuberger Berman Loan Advisers CLO 34 Ltd — 1.98%
- Ares LXXV CLO Ltd — 1.98%
- AIMCO CLO Series 2018-A — 1.97%
- Palmer Square CLO 2025-1 Ltd — 1.78%
- CIFC Funding 2024-III Ltd — 1.68%
FAQ
What is the difference between RAAR and NCLO?
RAAR (Reckoner Yield Enhanced AAA CLO Reinvesting ETF) and NCLO (Nuveen AA-BBB CLO ETF) are both etfs. But NCLO is far broader, holding 107 positions to 2 for RAAR, so beyond the top names it adds exposure RAAR doesn't have.
Should I own both RAAR and NCLO?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.